SEC Comment Letter 0000000000-23-001063 to RVL Pharmaceuticals plc (RVLPQ) (CIK 0001739426)
RVL Pharmaceuticals plc (RVLPQ) (CIK 0001739426)
Date: Feb. 1, 2023 · CIK: 0001739426 · Accession: 0000000000-23-001063
AI Filing Summary & Sentiment
File numbers found in text: 333-269440
Letter
United States securities and exchange commission logo February 1, 2023 Brian Markison Chief Executive Officer RVL Pharmaceuticals plc 400 Crossing Boulevard Bridgewater, NJ 08807 Re:RVL Pharmaceuticals plc Registration Statement on Form S-3 Filed January 27, 2023 File No. 333-269440 Dear Brian Markison: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Craig E. Marcus
Show Raw Text
United States securities and exchange commission logo
February 1, 2023
Brian Markison
Chief Executive Officer
RVL Pharmaceuticals plc
400 Crossing Boulevard
Bridgewater, NJ 08807
Re:RVL Pharmaceuticals plc
Registration Statement on Form S-3
Filed January 27, 2023
File No. 333-269440
Dear Brian Markison:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Craig E. Marcus